← Back to Search
Nδ-Methylated L-arginine Derivatives And Their Effects On The Nitric Oxide Generating System
J. Kotthaus, Dennis Schade, Katrin Töpker-Lehmann, E. Beitz, B. Clement
Published 2008 · Chemistry
Download PDFAnalyze on Scholarcy
Abstract So far N δ -methyl- l -arginine (MA) is only detected in yeast cells. Assuming that MA also exists in mammalians we examined possible physiological effects of N δ -methylated l -arginine derivatives on the nitric oxide generating system, that is, nitric oxide synthase (NOS), arginase and dimethylarginine dimethylaminohydrolase (DDAH). N δ -methyl- l -citrulline (MC) turned out to be a weak non-specific inhibitor of nitric oxide synthases. Moreover, MA is hydroxylated by all human NOS isoforms to N ω -hydroxy- N δ -methyl- l -arginine (NHAM) but not converted further. This hydroxylated intermediate, however, was detected to be a potent inhibitor of bovine liver arginase with a K i of 17.1 ± 2.2 μM.
This paper references
Reactions and significance of cytochrome P-450 enzymes.
F. Guengerich (1991)
Mutation of Glu-361 in Human Endothelial Nitric-oxide Synthase Selectively Abolishes L-Arginine Binding without Perturbing the Behavior of Heme and Other Redox Centers*
P. Chen (1997)
Microsomal cytochrome P450 dependent oxidation of N-hydroxyguanidines, amidoximes, and ketoximes: mechanism of the oxidative cleavage of their C=N(OH) bond with formation of nitrogen oxides.
A. Jousserandot (1998)
Nitric Oxide in the Pathogenesis of Cardiac Disease
L. Raij (2006)
S-Adenosylmethionine-dependent Methylation in Saccharomyces cerevisiae
A. Niewmierzycka (1999)
Upregulation of Vascular Arginase in Hypertension Decreases Nitric Oxide–Mediated Dilation of Coronary Arterioles
C. Zhang (2004)
Nitric oxide synthases: structure, function and inhibition.
W. K. Alderton (2001)
Potent and selective inhibition of neuronal nitric oxide synthase by N(ω)-propyl-L-arginine
H. Q. Zhang (1997)
2‐Amino‐4‐methylpyridine as a potent inhibitor of inducible NO synthase activity in vitro and in vivo
W. S. Faraci (1996)
ADVANCES IN PHARMACOLOGY
J. H. Burn (1957)
Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension
W. Xu (2004)
Isolation and Characterization of the Protein Components of the Liver Microsomal O2-insensitive NADH-Benzamidoxime Reductase*
B. Clement (1997)
Endothelial dysfunction and oxidative stress in arterial hypertension.
P. Ferroni (2006)
δ-N-Methylarginine Is a Novel Posttranslational Modification of Arginine Residues in Yeast Proteins*
P. Zobel-Thropp (1998)
Particular ability of liver P450s3A to catalyze the oxidation of N omega-hydroxyarginine to citrulline and nitrogen oxides and occurrence in no synthases of a sequence very similar to the heme-binding sequence in P450s.
J. P. Renaud (1993)
Nitric oxide and penile erectile function.
N. Toda (2005)
Bemerkungen zu der Abhandlung der HH. Weselsky und Benedikt „Ueber einige Azoverbindungen”
P. Griess (1879)
Nω-Hydroxyamino-α-amino acids as a new class of very strong inhibitors of arginases
J. Custot (1996)
The new alpha-amino acid N-omega-hydroxy-nor-L-arginine: A high-affinity inhibitor of arginase well adapted to bind to its manganese cluster
J. Custot (1997)
Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney.
T. Ogawa (1989)
Inhibition of rat liver arginase by an intermediate in NO biosynthesis, NG-hydroxy-L-arginine: implications for the regulation of nitric oxide biosynthesis by arginase.
F. Daghigh (1994)
Cytochrome P450 catalyzes the oxidation of N omega-hydroxy-L-arginine by NADPH and O2 to nitric oxide and citrulline.
J. L. Boucher (1992)
Selective substrate-based inhibitors of mammalian dimethylarginine dimethylaminohydrolase.
S. Rossiter (2005)
l-Arginine Binding to Nitric-oxide Synthase
B. R. Babu (1999)
A potent inhibitor of inducible nitric oxide synthase, ONO-1714, a cyclic amidine derivative.
M. Naka (2000)
N omega-hydroxyl-L-arginine, an intermediate in the L-arginine to nitric oxide pathway, is a strong inhibitor of liver and macrophage arginase.
J. L. Boucher (1994)
Microsomal formation of nitric oxide and cyanamides from non-physiological N-hydroxyguanidines: N-hydroxydebrisoquine as a model substrate.
B. Clement (1999)
Retention/quantitation properties of the o-phthaldialdehyde-3-mercaptopropionic acid and the o-phthaldialdehyde-N-acetyl-L-cysteine amino acid derivatives in reversed-phase high-performance liquid chromatography.
A. Vasanits (2000)
Classical and slow-binding inhibitors of human type II arginase.
D. M. Colleluori (2001)
Cytochrome P450 dependent N-hydroxylation of a guanidine (debrisoquine), microsomal catalysed reduction and further oxidation of the N-hydroxy-guanidine metabolite to the urea derivative. Similarity with the oxidation of arginine to citrulline and nitric oxide.
B. Clement (1993)
Synthesis of L-thiocitrulline, L-homothiocitrulline, and S-methyl-L-thiocitrulline: a new class of potent nitric oxide synthase inhibitors.
K. Narayanan (1994)
L-arginine analogs as alternate substrates for nitric oxide synthase.
Scott D. Luzzi (2005)
Thrombin Stimulates Human Endothelial Arginase Enzymatic Activity via RhoA/ROCK Pathway: Implications for Atherosclerotic Endothelial Dysfunction
X. Ming (2004)
Nitric oxide biosynthesis, nitric oxide synthase inhibitors and arginase competition for L-arginine utilization
J. L. Boucher (1999)
Determination of agmatine, arginine, citrulline and ornithine by reversed-phase liquid chromatography using automated pre-column derivatization with o-phthalaldehyde.
M. Patchett (1988)
Reduction of Nω-hydroxy-l-arginine to l-arginine by pig liver microsomes, mitochondria, and human liver microsomes
B. Clement (2006)
Oxidations of N(omega)-hydroxyarginine analogues and various N-hydroxyguanidines by NO synthase II: key role of tetrahydrobiopterin in the reaction mechanism and substrate selectivity.
C. Moali (2001)
Identification of the 4-amino analogue of tetrahydrobiopterin as a dihydropteridine reductase inhibitor and a potent pteridine antagonist of rat neuronal nitric oxide synthase.
E. Werner (1996)
NG-methyl-L-arginine functions as an alternate substrate and mechanism-based inhibitor of nitric oxide synthase.
N. M. Olken (1993)
This paper is referenced by
Dimethylarginine‐Dimethylaminohydrolase‐2 (DDAH‐2) Does Not Metabolize Methylarginines
Karin S Altmann (2012)
Arylazoamidoximes and Related Compounds as NO‐modulators
A. Schroeder (2010)
Prodrug design for the potent cardiovascular agent Nω-hydroxy-L-arginine (NOHA): synthetic approaches and physicochemical characterization.
D. Schade (2011)
Designing modulators of dimethylarginine dimethylaminohydrolase (DDAH): A focus on selectivity over arginase
J. Kotthaus (2012)
MS³ fragmentation patterns of monomethylarginine species and the quantification of all methylarginine species in yeast using MRM³.
T. Lakowski (2013)
Methylated N(ω)-hydroxy-L-arginine analogues as mechanistic probes for the second step of the nitric oxide synthase-catalyzed reaction.
Kristin Jansen Labby (2013)
Reduction of N(ω)-hydroxy-L-arginine by the mitochondrial amidoxime reducing component (mARC).
J. Kotthaus (2011)
Modulating the NO generating system from a medicinal chemistry perspective: current trends and therapeutic options in cardiovascular disease.
D. Schade (2010)
Arginase Structure and Inhibition: Catalytic Site Plasticity Reveals New Modulation Possibilities
J. Mortier (2017)
First detection and quantification of N(δ)-monomethylarginine, a structural isomer of N(G)-monomethylarginine, in humans using MS(3).
J. Martens-Lobenhoffer (2016)
Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads.
J. Kotthaus (2008)
Separation of the Structural Isomers of Monomethylarginine in Human Plasma by 2-D-HPLC and MS–MS Detection
J. Martens-Lobenhoffer (2016)